Abstract: Viral infections in a target region can be inhibited by imposing an alternating electric field in the target region for a duration of time. The alternating electric field has a frequency and a field strength such that when the alternating electric field is imposed in the target region for the duration of time, the alternating electric field inhibits infection of the cells in the target region by the virus. Optionally, the inhibition of viral infections using the alternating electric field approach can be combined with delivering an antiviral agent to the target region so that a therapeutically effective dose of the antiviral agent is present in the target region while the alternating electric fields are imposed.

Abstract: Tumor treating fields (TTFields) can be delivered by implanting a plurality of sets of implantable electrode elements within a person's body. Temperature sensors positioned to measure the temperature at the electrode elements are also implanted, along with a circuit that collects temperature measurements from the temperature sensors. In some embodiments, an AC voltage generator configured to apply an AC voltage across the plurality of sets of electrode elements is also implanted within the person's body.

Abstract: Tumors in portions of a subject's body that have a longitudinal axis (e.g., the torso, head, and arm) can be treated with TTFields by affixing first and second sets of electrodes at respective positions that are longitudinally prior to and subsequent to a target region. An AC voltage with a frequency of 100-500 kHz is applied between these sets of electrodes. This imposes an AC electric field with field lines that run through the target region longitudinally. The field strength is at least 1 V/cm in at least a portion of the target region. In some embodiments, this approach is combined with the application of AC electric fields through the target region in a lateral direction (e.g., front to back and/or side to side) in order to apply AC electric fields with different orientations to the target region.

Abstract: Tumor treating fields (TTFields) can be delivered by implanting a plurality of sets of implantable electrode elements within a person's body. Temperature sensors positioned to measure the temperature at the electrode elements are also implanted, along with a circuit that collects temperature measurements from the temperature sensors. In some embodiments, an AC voltage generator configured to apply an AC voltage across the plurality of sets of electrode elements is also implanted within the person's body.

Abstract: Tumors in portions of a subject's body that have a longitudinal axis (e.g., the torso, head, and arm) can be treated with TTFields by affixing first and second sets of electrodes at respective positions that are longitudinally prior to and subsequent to a target region. An AC voltage with a frequency of 100-500 kHz is applied between these sets of electrodes. This imposes an AC electric field with field lines that run through the target region longitudinally. The field strength is at least 1 V/cm in at least a portion of the target region. In some embodiments, this approach is combined with the application of AC electric fields through the target region in a lateral direction (e.g., front to back and/or side to side) in order to apply AC electric fields with different orientations to the target region.

Abstract: A transducer array for use in tumor-treating fields (TTFields) therapy is particularly suited for use in treating abdominal or thoracic cancers. The transducer array has features that increase its flexibility and adhesion to the patient's skin, including a branching configuration and a correspondingly branching top covering adhesive-backed layer. Additionally, a skin-level adhesive layer is provided beneath the flex circuit to which the electrode elements are attached, to help ensure thorough, lasting adhesion of the transducer array to the patient's skin over the course of treatment.

Abstract: A transducer array for use in tumor-treating fields (TTFields) therapy is particularly suited for use in treating abdominal or thoracic cancers. The transducer array has features that increase its flexibility and adhesion to the patient's skin, including a branching configuration and a correspondingly branching top covering adhesive-backed layer. Additionally, a skin-level adhesive layer is provided beneath the flex circuit to which the electrode elements are attached, to help ensure thorough, lasting adhesion of the transducer array to the patient's skin over the course of treatment.

Abstract: Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.

Abstract: This application discloses an improved approach for delivering Tumor Treating Fields (TTFields) at a therapeutically effective strength to the infratentorial regions of the brain. A first set of electrode elements is positioned on top of the head and a second set of electrode elements is positioned on the back of the neck. Third and fourth sets of electrode elements are positioned on the lower back right and the lower back left portions of the scalp, respectively. Applying an AC voltage between the first and second sets of electrode elements generates a generally vertical field in the infratentorial regions of the brain; and applying an AC voltage between the third and fourth sets of electrode elements generates a generally horizontal field in those regions.

Abstract: When electrodes are used to impose an electric field in target tissue within an anatomic volume (e.g., to apply TTFields to treat a tumor), the position of the electrodes can be optimized by generating a 3D map of electrical conductivity or resistivity of the anatomic volume. A location of the target tissue within the anatomic volume is identified, and a dipole is added to the 3D map at a location that corresponds to the target tissue. positions for the electrodes that maximize a potential attributable to the dipole are determined based on the 3D map of electrical conductivity or resistivity and the location of the dipole.

Abstract: When electrodes are used to impose an electric field in target tissue within an anatomic volume (e.g., to apply TTFields to treat a tumor), the position of the electrodes can be optimized by obtaining electrical conductivity measurements in an anatomic volume and generating a 3D map of the conductivity directly from the obtained electrical conductivity or resistivity measurements, without segmenting the anatomic volume into tissue types. A location of the target tissue is identified within the anatomic volume, and the positions for the electrodes are determined based on the 3D map of electrical conductivity and the position of the target tissue.

Abstract: The present disclosure provides a method for treating cancer in a patient harboring an EGFR-expressing tumor and/or tumor cell, such as glioblastoma, comprising the combination of (i) applying an AC electric field to a target area, wherein the target area comprises an EGFR-expressing tumor or cancer cell); and (ii) administering an effective amount of depatuxizumab mafodotin.

Abstract: Tumor treating fields (TTFields) can be delivered by implanting a plurality of sets of implantable electrode elements within a person's body. Temperature sensors positioned to measure the temperature at the electrode elements are also implanted, along with a circuit that collects temperature measurements from the temperature sensors. In some embodiments, an AC voltage generator configured to apply an AC voltage across the plurality of sets of electrode elements is also implanted within the person's body.

Abstract: A transducer array for use in tumor-treating fields (TTFields) therapy is particularly suited for use in treating abdominal or thoracic cancers. The transducer array has features that increase its flexibility and adhesion to the patient's skin, including a branching configuration and a correspondingly branching top covering adhesive-backed layer. Additionally, a skin-level adhesive layer is provided beneath the flex circuit to which the electrode elements are attached, to help ensure thorough, lasting adhesion of the transducer array to the patient's skin over the course of treatment.

Abstract: This application discloses an improved approach for delivering Tumor Treating Fields (TTFields) at a therapeutically effective strength to the infratentorial regions of the brain. A first set of electrode elements is positioned on top of the head and a second set of electrode elements is positioned on the back of the neck. Third and fourth sets of electrode elements are positioned on the lower back right and the lower back left portions of the scalp, respectively. Applying an AC voltage between the first and second sets of electrode elements generates a generally vertical field in the infratentorial regions of the brain; and applying an AC voltage between the third and fourth sets of electrode elements generates a generally horizontal field in those regions.

Abstract: Viral infections in a target region can be inhibited by imposing an alternating electric field in the target region for a duration of time. The alternating electric field has a frequency and a field strength such that when the alternating electric field is imposed in the target region for the duration of time, the alternating electric field inhibits infection of the cells in the target region by the virus. Optionally, the inhibition of viral infections using the alternating electric field approach can be combined with delivering an antiviral agent to the target region so that a therapeutically effective dose of the antiviral agent is present in the target region while the alternating electric fields are imposed.

Abstract: Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.

Abstract: Tumors in portions of a subject's body that have a longitudinal axis (e.g., the torso, head, and arm) can be treated with TTFields by affixing first and second sets of electrodes at respective positions that are longitudinally prior to and subsequent to a target region. An AC voltage with a frequency of 100-500 kHz is applied between these sets of electrodes. This imposes an AC electric field with field lines that run through the target region longitudinally. The field strength is at least 1 V/cm in at least a portion of the target region. In some embodiments, this approach is combined with the application of AC electric fields through the target region in a lateral direction (e.g., front to back and/or side to side) in order to apply AC electric fields with different orientations to the target region.